使Bocrelizumab

Delania Meng1,2, Rosaria Sacco1, Giulio Disanto1

  • 1Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland (NSI), Lugano, Switzerland.

Multiple sclerosis (Houndmills, Basingstoke, England)
|May 20, 2024
PubMed
概括

在多发性硬化症 (MS) 患者中,Ocrelizumab (OCR) 的个性化延长间隔 (EID) 剂量保持了临床和放射性疗效. 这种个性化的方法延长了输液间隔,为MS治疗提供了潜在的安全性和成本效益.